Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings

Investment firm increases stake in pharmaceutical company by 16% in Q3 2025.

Mar. 3, 2026 at 7:15am

Got story updates? Submit your updates here. ›

Wealthedge Investment Advisors LLC, a financial services firm, increased its stake in Bristol Myers Squibb Company (NYSE: BMY) by 16% in the third quarter of 2025. The firm now holds 112,152 shares of the biopharmaceutical company's stock, valued at $5,058,000 as of its most recent SEC filing.

Why it matters

Bristol Myers Squibb is a major pharmaceutical company focused on cancer, immunology, and other serious diseases. Wealthedge's increased investment signals confidence in the company's future performance and product pipeline.

The details

According to the 13F filing, Wealthedge Investment Advisors purchased an additional 15,466 shares of Bristol Myers Squibb during the third quarter, bringing its total position to 112,152 shares. This represents about 1.9% of Wealthedge's total investment portfolio. Bristol Myers Squibb is the 15th largest holding for the investment firm.

  • Wealthedge Investment Advisors increased its Bristol Myers Squibb stake in Q3 2025.

The players

Wealthedge Investment Advisors LLC

A financial services firm that manages investments for clients.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on discovering, developing, and delivering medicines for serious diseases.

Got photos? Submit your photos here. ›

The takeaway

Wealthedge's increased stake in Bristol Myers Squibb suggests the investment firm sees strong growth potential in the pharmaceutical company's portfolio of cancer, immunology, and specialty drugs.